Tyler Rehbein,Tong Tong Wu,Simona Treidler,Davide Pareyson,Richard Lewis,Sabrina W Yum,Brett A McCray,Sindhu Ramchandren,Joshua Burns,Jun Li,Richard S Finkel,Steven S Scherer,Stephan Zuchner,Michael E Shy,Mary M Reilly,David N Herrmann,Julian Blake,Kayla Cornett,Thomas O Crawford,Federica Rachele Danti,Gabrielle Donlevy,Katy Eichinger,Tim Estilow,Shawna M E Feely,Matilde Laura,Manoj Menezes,Isabella Moroni,Chiara Pisciotta,Alex Rossor,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary R Shy,Mariola Skorupinska,Janet E Sowden,Charlotte J Sumner,Dragan Vujovic,Inherited Neuropathy Consortium-Rare Diseases Clinical Research Network (INC-RDCRN)

Abstract:Recessive SH3TC2 variants cause Charcot-Marie-Tooth disease type 4C (CMT4C). CMT4C is typically a sensorimotor demyelinating polyneuropathy, marked by early onset spinal deformities, but its clinical characteristics and severity are quite variable. Clear relationships between pathogenic variants and the spectrum of disease manifestations are to date lacking. Gene replacement therapy has been shown to ameliorate the phenotype in a mouse model of CMT4C, emphasizing the need for natural history studies to inform clinical trial readiness. Data, including both genetic information and clinical characteristics, were compiled from the longitudinal, prospective dataset of the Inherited Neuropathy Consortium, a member of the Rare Diseases Clinical Research Network (INC-RDCRN). The Charcot Marie Tooth Neuropathy Score (CMTNS), Examination Score (CMTES) and the Rasch-weighted CMTES (CMTES-R) were used to describe symptoms, neurologic examinations, and neurophysiologic characteristics. Standardized response means were calculated at yearly intervals and a mixed model for repeated measures was used to estimate the change in CMTES and CMTES-R over time. 56 individuals (59% female), median age 27 years (range 2–67 years) with homozygous or compound heterozygous variants in SH3TC2 were identified, including 34 unique variants, 14 of which have not previously been published. 28 participants had longitudinal data available. While there was not a significant difference in the CMTES in those with protein-truncating versus non-protein-truncating variants, there were significant differences in the mean ulnar nerve compound muscle action potential amplitude, the mean radial sensory nerve action potential amplitude, and in the prevalence of scoliosis, suggesting the possibility of a milder phenotype in individuals with one or two non-protein-truncating variants. Overall, the mean value of the CMTES was 13, reflecting moderate clinical severity. There was a high rate of scoliosis (81%), scoliosis surgery (36%), and walking difficulty (94%) among study participants. The CMTES and CMTES-R appeared moderately responsive to change over extended follow-up, demonstrating a standardized response mean of 0.81 standard deviation units or 0.71 standard deviation units respectively, over 3 years. Our analysis represents the largest cross-sectional and only longitudinal study to date, of the clinical phenotype of both adults and children with CMT4C. With the promise of upcoming genetic treatments, this data will further define the natural history of the disease and inform study design in preparation for clinical trials.

AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C

AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease

Rescue of myocytes and locomotion through AAV2/9-2YF intracisternal gene therapy in a rat model of creatine transporter deficiency

Intrathecal gene therapy in mouse models expressing CMT1X mutations

O.09 Gene therapy of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)

AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model

Neuropathy due to bi-allelic SH3TC2 variants: Genotype-phenotype correlation and natural history

Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies

Aav9-Mediated Gene Therapy Of Choline Acetyltransferase Deficient Mice

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease

Gene Repair of Ipsc Line with GARS (G294R) Mutation of CMT2D Disease by CRISPR/Cas9

Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47

CSTB Gene Replacement Improves Neuroinflammation, Neurodegeneration and Ataxia in Murine Type 1 Progressive Myoclonus Epilepsy

Subpial delivery of adeno-associated virus 9-synapsin-caveolin-1 (AAV9-SynCav1) preserves motor neuron and neuromuscular junction morphology, motor function, delays disease onset, and extends survival in hSOD1G93A mice

Compound heterozygous mutations of SH3TC2 in Charcot–Marie–Tooth disease type 4C patients

Allele-Specific Gene Editing Rescues Pathology in a Human Model of Charcot-Marie-Tooth Disease Type 2E

Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations

Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot–Marie–Tooth type 1B mouse model

AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS

Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy